In vivo regulation of single copy and amplified N-myc in human neuroblastoma cells
- PMID: 9233765
- DOI: 10.1038/sj.onc.1201195
In vivo regulation of single copy and amplified N-myc in human neuroblastoma cells
Abstract
Amplification with subsequent overexpression of N-myc is a recurrent genomic alteration of neuroblastoma cells. DMS-in-vivo-footprinting of the basal promoter of the human N-myc gene (positions -221 to +21) revealed three changes in promoter architecture that are clustered in a 50 bp region and included (1) protein binding to two overlapping E2F-sites, (2) extreme hypersensitivity of guanine - 159, and (3) a short stretch of single stranded DNA with a single protected guanine. While in transient assays the basal promoter activated gene expression in all cell lines analysed, the changes at the endogenous promoter were restricted to neuroblastoma cells with strong N-myc expression. The hypersensitivity of guanine -159 could result from protein binding to a flanking, evolutionary conserved 5'-CCTCCC-3'-element, referred to as CT-box, that was bound in vitro in a Zn2+-requiring manner by a protein from nuclear extracts of neuroblastoma cells. Four copies of the CT-box in front of an N-myc minimal promoter (-60 to + 18) activated expression of a reporter gene in transient transfections whereas four copies of the mutant element did not. Our data add N-myc to a growing list of mammalian genes with CT-boxes that bind proteins in a Zn2+-dependent manner. Moreover, the data suggest that a common mechanism controls N-myc expression in neuroblastomas irrespective of N-myc copy number, and that in cell lines with amplification all gene copies contribute to N-myc expression.
Similar articles
-
Autoregulation of the human N-myc oncogene is disrupted in amplified but not single-copy neuroblastoma cell lines.Oncogene. 1997 Oct 16;15(16):1937-46. doi: 10.1038/sj.onc.1201363. Oncogene. 1997. PMID: 9365240
-
Cell type-specific expression and negative regulation by retinoic acid of the human N-myc promoter in neuroblastoma cells.Oncogene. 1992 Apr;7(4):711-7. Oncogene. 1992. PMID: 1565467
-
Transcriptional regulation of the mouse PNRC2 promoter by the nuclear factor Y (NFY) and E2F1.Gene. 2005 Nov 21;361:89-100. doi: 10.1016/j.gene.2005.07.012. Epub 2005 Sep 21. Gene. 2005. PMID: 16181749
-
Amplification of N-myc as a prognostic marker for patients with neuroblastoma.Semin Cancer Biol. 1993 Feb;4(1):13-8. Semin Cancer Biol. 1993. PMID: 8448374 Review.
-
The N-myc proto-oncogene: developmental expression and in vivo site-directed mutagenesis.Brain Pathol. 1992 Jan;2(1):71-83. Brain Pathol. 1992. PMID: 1341949 Review.
Cited by
-
MYCN Amplification in Neuroblastoma: a Paradigm for the Clinical Use of an Oncogene.Pathol Oncol Res. 1997;3(1):3-7. doi: 10.1007/BF02893344. Pathol Oncol Res. 1997. PMID: 11173617
-
ABCB1 Amplicon Contains Cyclic AMP Response Element-Driven TRIP6 Gene in Taxane-Resistant MCF-7 Breast Cancer Sublines.Genes (Basel). 2023 Jan 23;14(2):296. doi: 10.3390/genes14020296. Genes (Basel). 2023. PMID: 36833223 Free PMC article.
-
Hypoxia-Dependent Expression of TG2 Isoforms in Neuroblastoma Cells as Consequence of Different MYCN Amplification Status.Int J Mol Sci. 2020 Feb 18;21(4):1364. doi: 10.3390/ijms21041364. Int J Mol Sci. 2020. PMID: 32085516 Free PMC article.
-
Olig2 SUMOylation protects against genotoxic damage response by antagonizing p53 gene targeting.Cell Death Differ. 2020 Nov;27(11):3146-3161. doi: 10.1038/s41418-020-0569-1. Epub 2020 Jun 1. Cell Death Differ. 2020. PMID: 32483381 Free PMC article.
-
Metabolic characteristics of 13-cis-retinoic acid (isotretinoin) and anti-tumour activity of the 13-cis-retinoic acid metabolite 4-oxo-13-cis-retinoic acid in neuroblastoma.Br J Pharmacol. 2014 Dec;171(23):5330-44. doi: 10.1111/bph.12846. Br J Pharmacol. 2014. PMID: 25039756 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
